Discovery Life Sciences

Today, we are celebrating a series of groundbreaking advancements that mark the start of a new era for Discovery. The official opening of our brand-new state-of-the-art facilities in Huntsville, AL, and Alameda, CA, the launch of revolutionary Olink Explore HT services, and our revitalized website together will amplify our ability to empower scientists on a global scale.    "This trifecta of advancements signifies a profound moment in our journey," said Discovery CEO Glenn Bilawsky. "From Alameda to Huntsville, from the physical to the digital, we're reshaping the future of life sciences. We're more equipped than ever to catalyze innovations that have the potential to transform lives."  - Glenn Bilawsky, CEO of Discovery Life Sciences Visit our new website to learn more: https://lnkd.in/gHr-CZZ2

Discovery is a proud member of the Olink® CSP network, meeting all concordance testing requirements for offering Olink® Explore HT, Explore 3072/384, Target 96/48/Immune Surveillance, Flex, and Focus proteomic profiling services.  https://lnkd.in/gejFbcrY Our Olink® services require minimal sample input, preserving valuable samples, and our semi-automated and scalable workflows reduce turnaround time and minimize sample handling artifacts. Discovery’s QMS ensures rigorous sample and reagent tracking, data integrity, and comprehensive reports, especially for biopharma clinical trial biomarker studies. Our Olink® Target 48 services include per-project quality team process reviews and final study report signoffs.  Our additional proteomics services such as Luminex® and ThermoFisher Astral and Stellar mass spectrometry provide orthogonal breadth and depth in both liquid- and tissue-based proteomic applications. Speak with our proteomics experts today:  https://lnkd.in/gBbM9DTc

Access to a reliable source of diverse patient samples is crucial for studying autoimmune diseases, allowing for faster identification of unique disease patterns and the development of effective therapeutics and diagnostics.    Discovery specializes in prospective biospecimen collections and partners with nearly 200 clinical sites globally to provide a diverse range of autoimmune disease patient samples, including SLE, Crohn’s, rheumatoid arthritis, ulcerative colitis, sickle cell anemia, and more.    Let us help move your autoimmune disease research forward.  Discuss your project with us today: https://lnkd.in/gvV4TREc   #autoimmune #biospecimens 

Even though Sarcomas, a rare group of bone and soft tissue cancers, only account for < 1% of cancer cases in the United States, around 35% of diagnosed patients do not survive. Huge strides are being made, however, to develop immunotherapies to treat sarcoma. A recent American Society of Clinical Oncology (ASCO) article reviews the latest strategies under investigation, including immune checkpoint inhibitors (ICI), adoptive cellular therapies, and cancer vaccines:  https://lnkd.in/gbjERtDE  Discovery proudly supports the advancement of oncology research by providing scientists with essential tools and services. Together, we can develop innovative therapeutics and diagnostics that will change the lives of sarcoma patients. #SarcomaAwarenessMonth 

Curious about the impact of cryopreservation on dissociated tumor cells (DTCs)? Discovery’s cell biology expert, Dr. Shawn Fahl recently presented findings from three studies using single cell RNA/protein expression, immune repertoire profiling, and flow cytometry to explore this question during #EACR2024.  Watch the full recording of his talk here:      https://lnkd.in/eqDcj5BJ #oncology #cancerresearch #DTCs 

In recognition of the upcoming National Social Media Day on June 30th, we celebrate the power of social media in connecting people, ideas, and opportunities around the world. Today, we acknowledge the impact of platforms like LinkedIn in fostering professional relationships, sharing knowledge, and driving innovation. We recently reached 20,000 followers on LinkedIn - a testament to our commitment to connecting with all of you. We express our gratitude to our followers, partners, and colleagues around the world for supporting us on this digital journey. Your engagement, insights, and support have played a pivotal role in our success, and we are grateful for this vibrant community that continues to grow around our shared passion for advancing the development of innovative therapies and diagnostics. Let's continue this journey together! Your feedback, collaborations, and contributions are invaluable to us. Stay tuned for more exciting updates and insights from the world of Discovery Life Sciences. 

Discovery’s SpecimenSeq™ FFPE and Double-Spun Plasma (DSP) Matched Sets are trusted by liquid biopsy researchers for verifying biomarker targets, driver mutations, and clinically significant genomic variants. This inventory covers 2,000+ variants from 50+ clinically relevant genes across 30 oncology indications and 300+ unique patients. Supplies are limited, so reserve your SpecimenSeq™ FFPE and DSP Matched Sets today: https://lnkd.in/gyymRC6k #LiquidBiopsy #NGS #OncologyResearch 

Discovery proudly celebrates Juneteenth—the day that marks the end of slavery in America and the freedom of all Americans. Today and every day, we strive for inclusion and racial equality and seek to become better allies to our Black and African American friends and colleagues. Let’s keep the conversation going and work together towards a more equitable future for everyone.  #juneteeth #blacklivesmatter #freedom 

In a recent interview with Life Sciences Review, Jay Scherer, Discovery’s Chief Operating Officer, shared how our Science at Your Service philosophy enables our clients to ignite breakthroughs in precision medicine.    Read the article: https://lnkd.in/gSVvctJR Discovery is deeply committed to helping researchers worldwide advance therapies and improve patient outcomes. During his interview, Jay mentions that, “our team members and customers often share personal incidents of health challenges. These stories remind us that there is a patient with hope behind every sample we provide.” We believe each biospecimen sample and every service we provide could hold the key to the next significant medical breakthrough.  #PrecisionMedicine #Biospecimens #DrugDevelopment

Join us next week for an exciting webinar hosted by Agilent! Discovery’s Executive Vice President of Pathology and Medical Affairs, Dr. Hans-Ulrich Schildhaus, will moderate the conversation and share insights on HER2 testing.  Register today: https://lnkd.in/e3g854pr